Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMM-6-415 |
Synonyms | |
Therapy Description |
IMM-6-415 is a MEK inhibitor, which potentially reduces tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): A093). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMM-6-415 | IMM6415|IMM 6415|IMM-6415 | MEK inhibitor (Pan) 26 | IMM-6-415 is a MEK inhibitor, which potentially reduces tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): A093). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | colorectal cancer | predicted - sensitive | IMM-6-415 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, IMM-6-415 treatment inhibited tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (Mol Cancer Ther (2023) 22 (12_Supplement): A093). | detail... |
BRAF V600E | melanoma | predicted - sensitive | IMM-6-415 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, IMM-6-415 treatment inhibited tumor growth in a cell line xenograft model of melanoma harboring BRAF V600E (Mol Cancer Ther (2023) 22 (12_Supplement): A093). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06208124 | Phase Ib/II | IMM-6-415 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Recruiting | USA | 0 |